CN107648330A - A kind of hypoglycemic composition based on fennelflower and hypoglycemic anaesthetic - Google Patents
A kind of hypoglycemic composition based on fennelflower and hypoglycemic anaesthetic Download PDFInfo
- Publication number
- CN107648330A CN107648330A CN201711071958.XA CN201711071958A CN107648330A CN 107648330 A CN107648330 A CN 107648330A CN 201711071958 A CN201711071958 A CN 201711071958A CN 107648330 A CN107648330 A CN 107648330A
- Authority
- CN
- China
- Prior art keywords
- fennelflower
- composition
- parts
- hypoglycemic
- anaesthetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000008541 fennel flower Nutrition 0.000 title claims abstract description 75
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 28
- 230000003444 anaesthetic effect Effects 0.000 title claims abstract description 15
- 244000117495 fennel flower Species 0.000 title 1
- 244000090896 Nigella sativa Species 0.000 claims abstract description 78
- 239000003814 drug Substances 0.000 claims abstract description 25
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 21
- 235000005087 Malus prunifolia Nutrition 0.000 claims abstract description 17
- 244000070406 Malus silvestris Species 0.000 claims abstract description 17
- 240000007673 Origanum vulgare Species 0.000 claims abstract description 16
- 235000004383 Origanum vulgare subsp. vulgare Nutrition 0.000 claims abstract description 15
- 241001529246 Platymiscium Species 0.000 claims abstract description 13
- 244000116484 Inula helenium Species 0.000 claims abstract description 12
- 235000002598 Inula helenium Nutrition 0.000 claims abstract description 12
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 17
- 210000000582 semen Anatomy 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 241000196324 Embryophyta Species 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 2
- 230000003345 hyperglycaemic effect Effects 0.000 abstract description 2
- KEQHJBNSCLWCAE-UHFFFAOYSA-N thymoquinone Chemical compound CC(C)C1=CC(=O)C(C)=CC1=O KEQHJBNSCLWCAE-UHFFFAOYSA-N 0.000 description 18
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 13
- 230000037396 body weight Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 241000132446 Inula Species 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 235000016698 Nigella sativa Nutrition 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 240000005912 Nigella damascena Species 0.000 description 3
- 235000008750 Nigella damascena Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000001711 nigella sativa Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- ZRWJIZYZTLTXJI-UHFFFAOYSA-N Damascenine Chemical compound CNC1=C(OC)C=CC=C1C(=O)OC ZRWJIZYZTLTXJI-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000220225 Malus Species 0.000 description 2
- 241001518085 Nigella glandulifera Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XCYJPXQACVEIOS-UHFFFAOYSA-N 1-isopropyl-3-methylbenzene Chemical compound CC(C)C1=CC=CC(C)=C1 XCYJPXQACVEIOS-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 244000192024 Euphorbia helioscopia Species 0.000 description 1
- 235000012043 Euphorbia helioscopia Nutrition 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 235000010702 Insulata Nutrition 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000207955 Inula racemosa Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241001528553 Malus asiatica Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000007413 Nigella arvensis Nutrition 0.000 description 1
- HJKNBAAMIKPHJF-UHFFFAOYSA-N Nigellidine Natural products O=C1C2=C(c3ccc(O)cc3)N3N(C2=CC(C)=C1)CCCC3 HJKNBAAMIKPHJF-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 241001529744 Origanum Species 0.000 description 1
- 235000010677 Origanum vulgare Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229930007927 cymene Natural products 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- BYNDPWUDABJNCH-UHFFFAOYSA-N nigellidine Chemical compound [N+]=12CCCCN2C2=CC(C)=CC([O-])=C2C=1C1=CC=C(O)C=C1 BYNDPWUDABJNCH-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of hypoglycemic composition based on fennelflower, the composition includes the seed of fennelflower platymiscium, elecampane, Chinese pear-leaved crabapple skin and wild marjoram.Present invention simultaneously provides the hypoglycemic anaesthetic using above-mentioned composition as active component.Composition and anaesthetic provided by the invention can be used for the medicine for preparing preventing and treating hyperglycaemia or diabetes.The hypoglycemic effect highly significant of product provided by the invention, has good therapeutic action to hyperglycaemia and diabetes, and does not find any toxic side effect；For the raw material that the present invention uses for the plant of China's commerial growing, cost is low, great market development value, significant for the hyperglycemic patients of China's substantial amounts.
Description
Technical field
The present invention relates to pharmaceutical composition, and in particular to a kind of hypoglycemic composition based on fennelflower.
Background technology
The health of the diabetes serious threat mankind.According to the estimation of the World Health Organization, the whole world has 15,000,000 within 2012
People dies from diabetes, is the 8th the reason for causing death.It is another have 22,000,000 people increased because of hyperglycaemia angiocardiopathy and
The probability of other diseases such as kidney failure, its death factors are not listed in diabetes class.Such as International Diabetes Federation's estimation sugar
Urine disease causes 49,000,000 people dead, and its death is that diabetes are directly or indirectly caused.2016, there were 422,000,000 people in the whole world
With diabetes, wherein type ii diabetes account for 90%.The approach for the treatment of diabetes is to reduce blood sugar concentration at present.Medicine has orally
Such as melbine, it be treat type ii diabetes choice drug；Injection has GLP-1 receptor activators；And I type glycosurias
Disease can only insulin or its analog treat.
Fennelflower seed is the key component of a variety of traditional mongolian medicine prescriptions, and its content in various Prescription of Mongolian Medicine is minimum
2.73% (jewellery ball), up to 20% (5 taste fennelflower seeds dissipate).Fennelflower is annual plant, belongs to Ranunculaceae
(Ranunculaceae) fennelflower category (Nigella).This category has 18 kinds, it is common and rich in bioactive ingredients from
And the fennelflower platymiscium with medical value mainly has a fennelflower (Nigella sativa), Semen Nigellae (Nigella
Glandulifera Freyn＆Sint) and three kinds of fennelflower (Nigella damascena).There is open country on the ground such as Xinjiang of China, Tibet
Raw and cultivation Semen Nigellae.Family fennelflower has in countries such as India largely cultivates and is widely used in the cooking and folk medicine
Deng.The chemical composition analysis result of Semen Nigellae shows that its contained bioactive molecule is closely similar with family fennelflower seed, also contains
There are the bioactive substances such as polyunsaturated fatty acids and thymoquinone.Fennelflower seed used in Mongolian medicine, also cry " craze for Japanese pop culture-Sai La ",
" the conspicuous cloth in match Rana-towards lattice ", or " the refined load of color ", it is sweet, bitter, it is warm-natured, light, sharp, dry；Its effect is antipyretic, aid digestion, shield
Tooth；It is mainly used in：(1) stomach cold, the taste of asafoetide -8 can be entered；(2) hypofunction of liver, indigestion, hepatodynia, 8 taste Harrar Bao Er can be entered
Dissipate；(3) have a toothache, tooth auxotrophy, 5- taste fennelflower seeds can be entered and dissipated.The pharmaceutical procedures of Mongolian medicine's fennelflower seed are similar to Middle East
Traditional popular prescription.Such as 5 taste fennelflower seed dissipate and have solid tooth, an insecticidal action, and Egyptian suppresses toothache, oral cavity with pure fennelflower seed
Ulcer etc..Again for example, it is Egyptian it is among the people there's a widespread conviction that fennelflower seed can stablize and the immunity of enhancing human body, and contain fennelflower
The anaesthetic jewellery ball of son just has fine immunological enhancement.Modern medicine study found, family's fennelflower seed and its extract pair
Respiratory disease, anaphylactia, skin disease, hypertension, rheumatic arthritis and antitumaous effect etc..
Although morphologically difference is little for several fennelflowers, their microstructure and chemical composition has very big difference
Not.Such as family's fennelflower seed (Nigella sativa) and fennelflower seed (Nigella damascena) volatile ingredient,
In the content of unrighted acid composition and other important bioactive substances, there is huge difference.Family fennelflower
The most strong thymoquinone of bioactivity (Thymoquinone) is not present in fennelflower seed in son.And contain in Semen Nigellae
There is this small molecule active ingredient.The chemical composition and bioactivity of family fennelflower (Nigella sativa) are in western medicine
Widely studied.ω -3 in family's fennelflower seed, the serial content of unsaturated acid of ω -6, ω -9 is high, also containing a variety of volatilizations
The property active ingredient such as composition and thymoquinone.These chemical substances impart fennelflower seed inoxidizability, cancer resistance, anti-inflammatory,
So as to effectively prevent and alleviate the diseases such as allergic rhinitis, asthma, bronchitis, hypertension.Research shows, family fennelflower
Contained thymoquinone (Thymoquinone) has multiple biological activities in son.Studies in China Semen Nigellae (Nigella
Glandulifera Freyn＆Sint) chemical composition find its contain a variety of unrighted acids, thymoquinone,
Nigellidine, fennelflower glycosides, damascenine etc..Using extraction by steam distillation volatile oil, analysis finds Semen Nigellae
The thymoquinone content of son is 3.73%, and family's fennelflower seed is 3.80%, and fennelflower (Nigella damascena) is only
0.08%；The thymoquinone total content of Semen Nigellae is 1.58%, and family's fennelflower seed is 0.95% to 2.6%.All 50
In individual detection target chemical substances, two kinds of vegetable seeds chemical compositions, which have, compares having for significant difference：Between cymene (m-
Cymene), the former relative amount is 61.4%, and the latter 33.7%；Thymol, it is not detected by the former, Hou Zhewei
26.78%.Remaining each composition is not significantly different.As can be seen here, anaesthetic composition " craze for Japanese pop culture-Sai La " is Semen Nigellae
Bioactive ingredients are similar to family fennelflower seed, thus both plants very likely have identical drug effect, can replace mutually
Mend.
Although fennelflower seed has above bioactivity, the drug effect of single plant component, the conjunction of the nature and flavor such as shortcoming heat, cold
Reason collocation, so being difficult to reach preferable therapeutic effect, its drug effect has obvious limitation.
The content of the invention
It is an object of the invention to provide a kind of hypoglycemic composition based on fennelflower, and it has excellent hypoglycemic work
With, and without obvious toxic side effect, formula is simple, and raw material is easy to get.
Specifically, composition provided by the invention includes：The seed of fennelflower platymiscium, elecampane, Chinese pear-leaved crabapple skin and
Wild marjoram.
Wherein, the fennelflower platymiscium includes the one or more in fennelflower, family fennelflower, Semen Nigellae；
In practical application, present invention preferably employs family fennelflower, and Semen Nigellae is secondly.Fennelflower platymiscium of the present invention originates in
Ground is away from Mongolian plat, but in traditional mongolian medicine, and at least ten kinds of prescriptions contain fennelflower seed, and most prescriptions are with fennelflower seed
As main component.This has fully demonstrated the wisdom of " Make the past serve the present and foreign things serve China " of traditional Mongolian medicine, absorbs and adopts country variant
With the marrow of the medicine of national minorities；Importantly, Mongolia Medicine has given full play to the advantage of prescription, according to " cold-hot " of traditional Mongolian medicine
Theory, used with various important, conventional mongolian medicines and fennelflower seed collocation, excavated the life of fennelflower seed to greatest extent
Thing activity and therapeutic effect.Mongolian medicine's theory thinks that fennelflower seed is forgived；According to " gas-hila-Ba Da is done " theory and " cold-hot "
Theory, being used using high performance mongolian medicine and fennelflower seed collocation, the synergy that can give full play to medicine heightens the effect of a treatment,
Its potential toxic side effect can also effectively be reduced.Ground according to traditional popular prescription of family's fennelflower seed in original producton location, and modern pharmacy
The latest result studied carefully, in conjunction with the theory of Mongolian medicine's pharmacy, composition provided by the invention is based on the seed of fennelflower platymiscium
Raw material is wanted, using pure natural mongolian medicine as auxiliary material, it is possible to achieve good hypoglycemic effect.
Elecampane of the present invention is《Chinese Pharmacopoeia》The herbal medicine included, medicinal source are feverfew elecampane
(Inula helenium L.) or Tibet inula root (Inula racemosa Hook.f.) dry root.Autumn excavates, and removes mud
Sand, drying to obtain.There is a strengthening the spleen and stomach, promoting the flow of qi and relieving stagnancy, the effect of analgesic tocolysis, for chest side of body, abdominal distention, vomiting dysentery,
Chest side of body is dampened, and is felt a pain in the chest when breathing and is had a pain, fetal irritability.
Chinese pear-leaved crabapple skin of the present invention refers to rose family Malus Chinese pear-leaved crabapple (Malus asiatica Nakai) fruit
Real skin.Chinese pear-leaved crabapple is the distinctive plant in China, is distributed in the areas such as Heilungkiang, Jilin, Liaoning, Yunnan, Tibet, Inner Mongol, eats raw
Taste sweet and sour taste, has the effect of promoting the production of body fluid to quench thirst like apple.
Wild marjoram (scientific name of the present invention：Origanum vulgare L.) it is Labiatae, the perennial fruticuli of Origanum
Or herbaceous plant.This kind of all herbal medicine, can flu-prevention, control heatstroke, flu, headache body weight, stomachache, vomiting, fullness in chest, gas
Resistance food stagnation, infantile indigestion with food retention abdominal distension, diarrhoea, menorrhalgia, under uterine bleeding band, disease, its cold dispelling such as skin itching and oedema deliver function,
Especially it is better than peppermint.
The dosage of the seed of fennelflower platymiscium accounts for the composition gross mass in the preferably composition of the invention
More than 25%.
In order that giving full play to synergy in the composition between each component, subtract while realizing excellent hypoglycemic effect
Few toxic side effect, the present invention carry out preferred to the relative usage of each component.
Specifically, the present invention preferably composition includes the composition of following parts by weight：The seed of fennelflower platymiscium
15~25 parts, 20~28 parts of elecampane, 20~28 parts of Chinese pear-leaved crabapple skin, 20~28 parts of wild marjoram.
The further preferably composition of the invention includes the composition of following parts by weight：The seed 24 of fennelflower platymiscium~
25 parts, 24~26 parts of elecampane, 24~26 parts of Chinese pear-leaved crabapple skin, 24~26 parts of wild marjoram.
As a kind of optimal case of the present invention, the composition includes the composition of following parts by weight：Fennelflower category is planted
25 parts of the seed of thing, 25 parts of elecampane, 25 parts of Chinese pear-leaved crabapple skin, 25 parts of wild marjoram.
Composition provided by the invention distinguishes grind into powder in the preparation, by each raw material, is well mixed, you can must combine
Thing.
The present invention protects application of the composition in preventing and treating hyperglycaemia or diabetes medicament is prepared simultaneously.
The present invention further protects a kind of anaesthetic for being used to prevent and treat hyperglycaemia or diabetes, and it is with drop blood provided by the invention
Sugar composite is active component.In addition to the active constituents, the auxiliary material of pharmaceutical field permission can also be added, the present invention is not
Do particular determination.
As a preferred embodiment of the present invention, the anaesthetic is oral formulations, and active component therein passes through oral side
Formula plays a role after entering in vivo.
In order to improve the bioavilability of the oral formulations, the present invention carries out excellent to the specific formula of the oral formulations
Change.Specifically, the carboxylic first for accounting for the active component quality 5~10% is also included in addition to the active component, in the preparation
Base sodium starch.The present invention may insure that active component passes through mouth in anaesthetic by largely putting into practice discovery using above-mentioned specific formula
Clothes can be fully absorbed by intestines and stomach, so as to give full play to its blood sugar decreasing effect.
In practical application, the safe dose of active ingredient refers to 1000mg/kg body weight in the anaesthetic.
Compared with prior art, the hypoglycemic effect highly significant of product provided by the invention, better than existing medicine diformazan
Biguanides, there is good therapeutic action to hyperglycaemia and diabetes, and do not find any toxic side effect；The original that the present invention uses
Expect the plant for China's commerial growing, cost is low, great market development value, for the hyperglycemic patients of China's substantial amounts
It is significant.
Brief description of the drawings
Fig. 1 is that fennelflower is formulated the influence result schematic diagram to STZ blood glucose in diabetic rats in experimental example；
Fig. 2 is the influence result schematic diagram of blank group STZ diabetes rat body weights in experimental example；
Fig. 3 is the influence result schematic diagram of model group STZ diabetes rat body weights in experimental example；
Fig. 4 is the influence result schematic diagram of positives group of STZ diabetes rat body weight of experimental example；
Fig. 5 is the influence result schematic diagram of low dosage administration group STZ diabetes rat body weights in experimental example；
Fig. 6 is the influence result schematic diagram of high dose administration group STZ diabetes rat body weights in experimental example.
Embodiment
Following examples are used to illustrate the present invention, but are not limited to the scope of the present invention.
In following embodiment, the fennelflower seed refers to the seed of a fennelflower.
Embodiment 1
A kind of hypoglycemic composition is present embodiments provided, is by fennelflower seed powder 25g, Inula Root 25g, Chinese pear-leaved crabapple
Skin powder 25g and wild marjoram powder 25g are mixed.
Embodiment 2
A kind of hypoglycemic composition is present embodiments provided, is by fennelflower seed powder 15g, Inula Root 20g, Chinese pear-leaved crabapple
Skin powder 20g and wild marjoram powder 20g are mixed.
Embodiment 3
A kind of hypoglycemic composition is present embodiments provided, is by fennelflower seed powder 25g, Inula Root 28g, Chinese pear-leaved crabapple
Skin powder 28g and wild marjoram powder 28g are mixed.
Embodiment 4
A kind of hypoglycemic composition is present embodiments provided, is by fennelflower seed powder 25g, Inula Root 10g, Chinese pear-leaved crabapple
Skin powder 10g and wild marjoram powder 10g are mixed.
Embodiment 5
A kind of hypoglycemic composition is present embodiments provided, is by fennelflower seed powder 25g, Inula Root 50g, Chinese pear-leaved crabapple
Skin powder 50g and wild marjoram powder 50g are mixed.
Comparative example 1
Compared with Example 1, differ only in：The elecampane is replaced with radix glycyrrhizae.
Comparative example 2
Compared with Example 1, differ only in：The Chinese pear-leaved crabapple skin is replaced with wolf's milk.
Comparative example 3
Compared with Example 1, differ only in：The wild marjoram is replaced with seed of garden lettuce.
Comparative example 4
A kind of Traditional Chinese medicine for decreasing blood sugar, i.e. sugar-reducing comfort piece (or capsule), formula are specially：Ginseng, the Radix Astragali, the dried rhizome of rehmannia, sealwort, thorn
Slender acanthopanax and the red sage root；Above each component combines according to dosage disclosed in sugar-reducing comfort piece.
Experimental example
1st, experiment material
Animal：Wistar rats, body weight 200g.SPF levels, raise in 22 DEG C, constant humidity 50%, each 12h of artificial lighting light and shade
Animal housing in, feed one week adaptation after modeling.
Reagent：0.5%CMC-Na：1g CMC-Na add 200mL pure water, stirring；
Streptozotocin (streptozotocin, STZ)：Sigma companies, article No.；S0130, lot number (Lot#)：
WXBC2544V
Instrument and equipment：Assay balance (Ohaus)
1ml asepsis injectors；
Roche blood glucose meter vigor type：(ACCU-CHEK Active, Roche companies)；Blood sugar test paper：LOT 24672231
2nd, experimental method
1) acute toxicity testing：
KM mouse, body weight 20g, each 10 of male and female, gastric infusion, the dynamical state of 2 days after record administration；
2) hypoglycemic is tested：
Wistar rats, body weight 200g, divide 5 groups, every group 6 only to 9；Blank group：6；Model group：40；
STZ modelings, dosage 60mg/kg is injected intraperitoneally；72 as a child took a blood sample, and measure blood sugar concentration >=11.1mmoL/L sentences
It is set to and models successfully；
To the successful animal of modeling, it is grouped, is divided into 4 groups：Model group, positive controls, hypoglycemic composition (are implemented
Example 1 provides) low dosage, hypoglycemic composition (embodiment 1 provides) high dose group；Melbine, dosage is administered in positive controls
For 260mg/kg；Low dose group dosage is 60mg/kg；High dose group dosage is 120mg/kg；Each group is administered daily 1
It is secondary, successive administration 21 days；
The activity of each group animal, feed, fur, defecation, spirit, perpendicular hair etc. are recorded during experiment；Weigh and record body weight
Change.
3rd, experimental result
Acute toxicity testing the results are shown in Table 1.
Table 1：Mouse Acute Toxicity experimental result summary sheet
Influence result of the fennelflower formula to STZ blood glucose in diabetic rats (* P in figure as shown in Figure 1<0.05vs models；**
P<0.01vs models).Influence result of the fennelflower formula to STZ diabetes rat body weights is as figures 2-6.
4th, experiment conclusion
Composition acute toxicity very little provided by the invention, there is obvious hypoglycemic to make the hyperglycemia animal of STZ guiding
With；And be dose dependent, the hypoglycemic efficiency of low dosage (60mg/kg) is high apparently higher than melbine (260mg/kg)
The blood sugar reducing function of dosage (120mg/kg) is more prominent.
The present invention detects according to the method for above-mentioned experimental example to the effect of remaining embodiment and comparative example, as a result shows
The blood sugar decreasing effect of embodiment 2~5 is relatively low compared with embodiment 1, but is better than comparative example 1~4；And the effect of reducing blood sugar of comparative example 1~4
The equal conspicuousness of fruit is less than embodiment 1.
Analysis is understood：Main component fennelflower seed content is below 25% in embodiment 2,3,5, and therefore, hypoglycemic effect is low
In embodiment 1；In embodiment 4, the content of 4 kinds of components is not within optimal balance point, therefore its blood sugar decreasing effect is also below reality
Apply example 1.Comparative example 1~3 substituted for the medicament categories in embodiment 1 respectively, cause to be formulated the forfeiture of interior active ingredient, ratio mistake
Adjust, its hypoglycemic effect is substantially less than formula listed in embodiment 1；Compared with the sugar-reducing comfort that comparative example 4 provides, of the invention matches somebody with somebody
Fang Zufang is simpler, and toxicity is low, and hypoglycemic effect has significant advantage.
Although above the present invention is made to retouch in detail with general explanation, embodiment and experiment
State, but on the basis of the present invention, it can be made some modifications or improvements, this is apparent to those skilled in the art
's.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, are belonged to claimed
Scope.
Claims (10)
- A kind of 1. hypoglycemic composition based on fennelflower, it is characterised in that including：The seed of fennelflower platymiscium, elecampane, Chinese pear-leaved crabapple skin and wild marjoram.
- 2. composition according to claim 1, it is characterised in that the fennelflower platymiscium includes fennelflower, black race of family One or more in grass, Semen Nigellae, preferably family fennelflower.
- 3. composition according to claim 1 or 2, it is characterised in that the dosage of the seed of the fennelflower platymiscium accounts for More than the 25% of the composition gross mass.
- 4. composition according to claim 1 or 2, it is characterised in that include the composition of following parts by weight：Fennelflower category is planted 15~25 parts of the seed of thing, 20~28 parts of elecampane, 20~28 parts of Chinese pear-leaved crabapple skin, 20~28 parts of wild marjoram.
- 5. composition according to claim 4, it is characterised in that include the composition of following parts by weight：Fennelflower platymiscium 24~25 parts of seed, 24~26 parts of elecampane, 24~26 parts of Chinese pear-leaved crabapple skin, 24~26 parts of wild marjoram.
- 6. according to the composition described in Claims 1 to 5 any one, it is characterised in that each raw material is distinguished into grind into powder, It is well mixed, produce composition.
- 7. a kind of hypoglycemic anaesthetic, it is characterised in that using composition described in claim 1~6 any one as active component.
- 8. anaesthetic according to claim 7, it is characterised in that the anaesthetic is oral formulations.
- 9. anaesthetic according to claim 8, it is characterised in that also comprising the carboxylic for accounting for the active component quality 5~10% Methyl starch sodium.
- 10. anaesthetic described in composition described in claim 1~6 any one or claim 7~9 any one is preparing preventing and treating Application in hyperglycaemia or diabetes medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711071958.XA CN107648330B (en) | 2017-11-03 | 2017-11-03 | Blood sugar reducing composition based on nigella sativa and mongolian medicine for reducing blood sugar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711071958.XA CN107648330B (en) | 2017-11-03 | 2017-11-03 | Blood sugar reducing composition based on nigella sativa and mongolian medicine for reducing blood sugar |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107648330A true CN107648330A (en) | 2018-02-02 |
| CN107648330B CN107648330B (en) | 2021-03-23 |
Family
ID=61096749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711071958.XA Expired - Fee Related CN107648330B (en) | 2017-11-03 | 2017-11-03 | Blood sugar reducing composition based on nigella sativa and mongolian medicine for reducing blood sugar |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107648330B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111019010A (en) * | 2019-12-31 | 2020-04-17 | 河南大学 | Nigella sativa seed polysaccharide, extraction method and application in preparation of medicament for treating type 2 diabetes |
| CN113341048A (en) * | 2021-07-02 | 2021-09-03 | 锡林郭勒职业学院 | Quality evaluation method of nigella sativa prescription |
-
2017
- 2017-11-03 CN CN201711071958.XA patent/CN107648330B/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111019010A (en) * | 2019-12-31 | 2020-04-17 | 河南大学 | Nigella sativa seed polysaccharide, extraction method and application in preparation of medicament for treating type 2 diabetes |
| CN111019010B (en) * | 2019-12-31 | 2021-10-29 | 河南大学 | Nigella sativa seed polysaccharide, extraction method and application in preparation of medicament for treating type 2 diabetes |
| CN113341048A (en) * | 2021-07-02 | 2021-09-03 | 锡林郭勒职业学院 | Quality evaluation method of nigella sativa prescription |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107648330B (en) | 2021-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101972338B (en) | Chinese medicinal preparation for treating infantile upper respiratory tract infection and preparation method thereof | |
| CN102078419B (en) | Medicament for preventing and treating porcine reproductive and respiratory syndrome (PRRS) and preparation method thereof | |
| CN103585433B (en) | Traditional Chinese medicine composition for treating oral ulcer | |
| CN102845745A (en) | Dendrobium officinale health-care product | |
| CN104027529A (en) | Traditional Chinese medicine composition for regulating blood lipids, blood pressure and blood glucose and preparation method thereof | |
| Shahrajabian et al. | A short review of goji berry, ginger, ginseng and astragalus in traditional Chinese and Asian medicine | |
| CN104784505A (en) | Dendrobium officinale healthcare product with auxiliary blood glucose reducing function and preparation method thereof | |
| CN107648330A (en) | A kind of hypoglycemic composition based on fennelflower and hypoglycemic anaesthetic | |
| CN104491672A (en) | Traditional Chinese medicine preparation for treating chronic tracheitis and preparation method thereof | |
| CN104491802A (en) | Application of traditional Chinese medicine preparation in preparation of medicine for treating acute or chronic gastritis | |
| CN105327115B (en) | A kind of prevention and treatment type II diabetes Phellinus is logical to rush down formula and preparation process | |
| CN104257839B (en) | A kind of Chinese medicine composition with hypoglycemic protection blood vessel endothelium effect and preparation method thereof | |
| CN103550739B (en) | Traditional Chinese medicinal composition for treating acute enteritis and preparation method of traditional Chinese medicinal composition | |
| CN113826882A (en) | Dietary nutrition supplement for preventing and treating diabetes and preparation process thereof | |
| CN106377700A (en) | Folium mori and bitter gourd tea and making method thereof | |
| CN104547859A (en) | Application of traditional Chinese medicine preparation in preparation of medicine for treating chronic tracheitis | |
| CN104436022A (en) | Hemsleya-macrosperma-containing traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104096073A (en) | Traditional Chinese medicine composition for treating male infertility and preparation method for same | |
| CN103655999A (en) | Drug for preventing and curing avian influenza and preparation method thereof | |
| CN103263580A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN114306544B (en) | Hypoglycemic composition and preparation method thereof | |
| CN101574427B (en) | Traditional Chinese medicine compound for aiding drug rehabilitation and traditional Chinese medicine containing same | |
| CN108542965B (en) | Burdock root honey tablets and preparation method and application thereof | |
| CN105582379A (en) | Traditional Chinese medicine composition for treating liver-stomach disharmony and preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210323 |